Antiangiogenic therapy for ovarian cancer

Česká verzia

Authors: Petra Tesařová
Authors place of work: Onkologická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. Luboš Petruželka, CSc.
Published in the journal: Prakt Gyn 2013; 17(1): 40-46
Category: Oncogynecology: Review Article

Summary

Epithelial tumours of the ovary, fallopian tube or peritoneum (epithelial ovarian cancer – EOC) manifest similar behavioral characteristics. An important condition for their development is the provision of blood supply through the tumour bloodstream. The main growth factor controlling the tumour angiogenesis is the vascular endothelial growth factor (VEGF). Angiogenesis plays an essential role within the normal ovarian physiology, pathogenesis of epithelial ovarian cancer (EOC), progression of tumour mass and arising of ascites also in metastatic dispersal. VEGF and its receptor VEGFR are expressed in the EOC cells and their concentration increases within the development of the malign ascites. This is the reason why VEGF and its receptor should be considered as the potential treatment targets in relation to the EOC [1].

Key words:
bevacizumab – epithelial ovarian cancer – ovarian carcinoma – vascular endothelial growth factor – VEGF – VEGFR – PGF

Zdroje

1. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14(6): 901–918.

2. Ramakrishnan S, Subramanian IV, Yokoyama Y et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8(2): 169–182.

3. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121(1): 230–238.

4. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(33): 5165–5171.

5. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26(1):76–82.

6. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008; 110(1):49–55.

7. Aghajanian C, Blank SV, Goff BA et al. OCEANS: A Randomized, Double-Blind, Placebo-ControlledPhase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol 2012; 30(17): 2039–2045. Dostupné z doi: 10.1200/JCO.2012.42.0505.

8. Pujade-Lauraine E, Hilpert F and AURELIA Investigators: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012; 30(18: Suppl 2012 ASCO Annual Meeting Abstracts): abstr LBA5002.

9. Poveda AM, Selle F, Hilpert F et al. Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Program and abstracts of the 2012 Annual Congress of the European Society for Medical Oncology; September 28-October 2, 2012; Vienna, Austria. Abstract LBA26.

10. Azad NS, Annunziata CM, Steinberg SM et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008; 112(8):1726–1732.

11. Diaz JP, Tew WP, Zivanovic O et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010; 116(3): 335–339.

12. Richardson DL, Backes FJ, Hurt JD et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 2010; 118(1):47–51.

13. Coleman RL, Duska LR, Ramirez PT et al. Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011; 12(12): 1109–1117.

14. Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30(4): 362–371.

15. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29(28): 3798–3804.

16. Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011; 29(1): 69–75.

17. Friedlander M, Hancock KC, Rischin D et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119(1): 32–37.

18. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27(33): 5601–5606.

19. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005; 11(15): 5539–5548

20. Schilder R, Sill M, Lee R et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2008; 26(20): 3418–3425.

21. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109(2): 182–186.

22. Behbakht K, Sill MW, Darcy KM et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 2011; 123(1): 19–26.

23. Usha L, Sill MW, Darcy KM et al. A Gynecologic Oncology Group Phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011; 121(3): 455–461.

24. Rocereto TF, Brady WE, Shahin MS et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 2010; 116(3): 332–334.